Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2017 call → NOWe need answer YES or NO based on transcript. Need determine if management describes company currently living through defined waiting period paying out of pocket, with cost currently landing, main current work, and specific near-dated event already visible and working toward. Let's parse transcript. Company Pacira, EXPAREL. They have manufacturing expansion in UK. Charlie: "we continue to invest in expansion of manufacturing facilities in UK with first commercial manufacturing on track to begin in second half of 2018. As we continue to build additional manufacturing capacity at this location and it becomes fully responsible for supplying EXPAREL, we expect non-GAAP EXPAREL margins to improve to roughly 85%." Also R&D includes "200 liter scale up of manufacturing capabilities in UK." Dave later discusses spray process, batch, UK. He says "We have plenty of capacity from our current facilities in San Diego and our online facilities coming late this year in Swindon. We will give Swindon as much material as they can make, because it is an improved gross margin. And then we will queue improve gross margin and then, we will QS that with San Diego until we get a 200 liter up. And we have until the end of the year frankly to decide whether that will be batch and/or a spray." This sounds like they are investing in manufacturing capacity, paying now for expansion, benefit not yet arrived (first commercial manufacturing second half 2018). Is this a defined waiting period? They are currently bearing costs? R&D expenses include scale-up. Gross margin currently 70-72%, expected to improve to 85% when UK fully responsible. But is that "paying now for something not yet earning"? They are building facility, first commercial manufacturing on track second half 2018. That is a specific near-dated event. Management speaks as though wait is main current work? They discuss many things, but manufacturing expansion is one of key drivers. They are not apologizing, they are investing. However, is the cost real and currently landing in results? Yes, R&D expenses include scale-up, SG&A etc. But is it "paying for something not yet earning"? The UK facility is not yet producing commercial product, but they already have San Diego producing and earning. The expansion is to improve margins and capacity. The company is currently earning from existing product.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.